Basel, Switzerland

Thomas Müggler


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Thomas Müggler: Innovator in Alzheimer's Disease Research**

Introduction

Thomas Müggler, based in Basel, Switzerland, is a prominent inventor known for his significant contributions to Alzheimer's disease research. His innovative approach has paved the way for new understanding and potential treatment pathways for this complex neurodegenerative condition.

Latest Patents

Müggler holds a patent for a "Transgenic Animal Model for Alzheimer's Disease". This innovative patent outlines a novel APP (amyloid precursor protein) transgenic non-human animal model, which serves to study in vivo the pathophysiological effects of amyloid-β (Aβ) deposition and cerebral amyloid angiopathy. This model also examines the cognitive behavior associated with brain microhemorrhages and the impact on vasoreactivity and blood flow. Importantly, the patent provides methods for screening therapeutic or diagnostic agents that could be beneficial for treating or diagnosing Alzheimer's disease, specifically aimed at improving cerebral blood flow.

Career Highlights

Müggler's work at the University of Zurich has established him as a key figure in the field of neuroscience. His singular focus on advancing the understanding of Alzheimer's disease through innovative research methods has resulted in meaningful breakthroughs, especially in animal modeling that reflects human pathophysiology.

Collaborations

Throughout his career, Müggler has collaborated with esteemed colleagues such as Jan Grimm and Roger Nitsch. Their collective expertise contributes to a robust research environment, fostering innovative approaches to tackle the challenges posed by Alzheimer's disease.

Conclusion

Thomas Müggler stands out as a dedicated inventor whose work is making a significant impact in the understanding and potential treatment of Alzheimer's disease. His innovative patented model and collaborative research initiatives at the University of Zurich are crucial to advancing neurological science and paving the way for future therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…